Frequently asked questions
CJC-1295: the questions readers ask most, answered from the record
Safety, regulatory status, the steroid question, the testosterone question, and the dose questions — each answered directly and cited to the literature.
Reported and theoretical concerns in the literature
CJC-1295 side effects in the record arise from sustained GH/IGF-1 elevation: fluid retention and edema, effects on insulin sensitivity, and the epidemiological link between higher IGF-1 and modestly increased risk of certain cancers. FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity and other safety concerns for GH secretagogues including CJC-1295. Safety in healthy adults is not established; the human evidence is limited to early pharmacokinetic studies [1] [3]. The answers below address the questions readers ask most, each cited to that record.
What is CJC-1295?
A synthetic GHRH analog built on hGRF(1-29) with four protease-resistant substitutions [2]. The DAC variant covalently binds serum albumin for a multi-day half-life [1], while the no-DAC form (Modified GRF 1-29) is short-acting. It stimulates the body's own pulsatile GH release rather than supplying GH directly [1].
What does CJC-1295 do?
It binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile growth-hormone release and a downstream rise in hepatic IGF-1 [1]. In human studies a single subcutaneous dose raised GH and IGF-1 for days while preserving the pituitary's pulsatile rhythm [1] [3].
Is CJC-1295 a steroid?
No. CJC-1295 is a peptide GHRH analog that stimulates the body's own growth-hormone axis [1] — it is not an anabolic-androgenic steroid. Steroids are lipid-based hormones acting on intracellular receptors; CJC-1295 acts on the GHRH receptor, a cell-surface G-protein-coupled receptor, to raise GH and IGF-1.
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved for human use. It was reviewed and not recommended for the FDA 503A compounding bulks list at the 2024 Pharmacy Compounding Advisory Committee. It is sold and handled as a research chemical, with no approved human indication anywhere.
Is CJC-1295 safe?
CJC-1295 is unapproved for human use, and safety in healthy adults is not established. Published human data are limited to early pharmacokinetic studies [1] [3], and sustained GH/IGF-1 elevation raises theoretical concerns including fluid retention, effects on insulin sensitivity, and IGF-1/cancer epidemiology. FDA briefing materials for the 2024 PCAC cited immunogenicity concerns for GH secretagogues including CJC-1295.
Are CJC-1295 peptides safe?
Safety in healthy adults is not established. FDA briefing materials for the 2024 PCAC cited immunogenicity and other safety concerns for GH secretagogues including CJC-1295. The peer-reviewed human record consists of early pharmacokinetic studies in volunteers [1] [3]; no controlled trial has assessed long-term safety.
What are the side effects of CJC-1295?
Reported and theoretical concerns include fluid retention and edema, effects on insulin sensitivity, and IGF-1/cancer-risk epidemiology from sustained GH-axis stimulation. These follow from chronic GH/IGF-1 elevation rather than from controlled adverse-event trials, because the human evidence is limited to early pharmacokinetic studies [1] [3].
Does CJC affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis [1]. The published human studies report GH and IGF-1 outcomes and do not establish a testosterone effect [1] [3]. There is no characterized mechanism by which CJC-1295 directly alters testosterone.
Does CJC-1295 lower testosterone?
There is no published human evidence that CJC-1295 lowers testosterone. Its characterized action is on the GH/IGF-1 axis [1] [3], not the hypothalamic-pituitary-gonadal axis, and the human PK studies reported no testosterone effect.
What to expect when taking CJC-1295?
Published human data describe dose-dependent multi-day GH and IGF-1 elevation after a single subcutaneous dose [1] [3]. Broader physiological expectations in healthy adults — strength, body composition, recovery — are not established by controlled trials. The literature characterizes a hormone-axis response and stops there [1] [3].
What is CJC-1295 DAC?
CJC-1295 with the Drug Affinity Complex moiety — the long-acting, albumin-conjugated form, as opposed to the short-acting no-DAC Modified GRF 1-29 [2]. Its plasma half-life was estimated at 5.8 to 8.1 days in healthy adults, the multi-day duration that defines the form [1].
What is CJC-1295 with DAC?
The variant whose C-terminal lysine carries a maleimidopropionyl linker that covalently bonds to serum albumin, extending the plasma half-life toward that of albumin itself [2]. The albumin conjugation is what produces the multi-day GH/IGF-1 elevation seen in human studies [1].
How much CJC-1295 DAC should I take?
There is no approved human dose; CJC-1295 is not approved for human use. DAC's 5.8-to-8.1-day half-life is why the GHRH-knockout-mouse work used once-daily dosing [4]; human PK studies used 30-to-90 µg/kg single subcutaneous doses [1] [3]. Those are study doses, not a recommendation.
How much CJC-1295 should I take?
There is no recommended human dose. Human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 µg/kg [1] [3]; these are study doses, not a human dosing recommendation, and CJC-1295 is not approved for human use. Fixed-microgram 'protocols' online lack a controlled-trial basis.
How to reconstitute CJC-1295?
In research handling the lyophilized peptide is reconstituted with bacteriostatic water and refrigerated [2]. This is described as laboratory handling context, not a use instruction for a compound that is not approved for human use.
Where to inject CJC-1295?
Studies used the subcutaneous route; oral bioavailability is negligible [1]. This is the route the research used, not a use instruction — CJC-1295 has no approved human indication.
What is CJC-1295 ipamorelin?
A research pairing of a long-acting GHRH analog (CJC-1295) with a selective GH secretagogue (ipamorelin) that engages a second receptor pathway [9]. The two receptors are distinct, so their GH-release effects are supra-additive [7]. It is not an approved therapy and has no controlled outcome trial.
Why is CJC-1295 often paired with ipamorelin?
Because GHRH analogs and GHRPs act on separate receptors and their GH release is supra-additive [7]. Ipamorelin is the usual partner because it was the first selective GH secretagogue, releasing GH with minimal ACTH/cortisol or prolactin spillover [9]. CJC-1295 supplies the long-acting GHRH-receptor arm; ipamorelin the secretagogue arm.
Does CJC-1295 and ipamorelin work?
For raising growth hormone, yes in mechanism: GHRH and GHRP act through distinct receptors and synergize, producing GH release greater than the sum of either alone in human studies [7]. For body-composition or performance outcomes, no controlled trial has tested the CJC-1295/ipamorelin pairing [1] [3].
How much CJC-1295 / ipamorelin should I take?
Human PK studies used single subcutaneous doses of 30, 60, or 90 µg/kg of CJC-1295 [1] [3]. Community CJC-1295/ipamorelin protocols cite 100-to-300 µg fixed doses, but these are not derived from controlled human trials. There is no approved human dose for either compound.
How do I use CJC-1295 and ipamorelin?
In research handling both are lyophilized peptides reconstituted with bacteriostatic water and given subcutaneously; oral bioavailability is negligible [1]. No approved human protocol exists. This is laboratory handling context, not a use instruction for compounds that are not approved for human use.
Will CJC-1295/ipamorelin give good results with weight loss and muscle building?
The peer-reviewed evidence in healthy adults is thin and short-term. IGF-1 drives muscle-hypertrophy signaling in principle, but no controlled CJC-1295 trial reports body-composition outcomes [1] [3], and no trial has tested the CJC-1295/ipamorelin pairing for weight loss or muscle building.